Market closedADR
Burning Rock Biotech/$BNR
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Burning Rock Biotech
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through our in-hospital model and smaller hospitals through our central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
Ticker
$BNR
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
786
Website
BNR Metrics
BasicAdvanced
$68M
Market cap
-
P/E ratio
-$5.71
EPS
0.60
Beta
-
Dividend rate
Price and volume
Market cap
$68M
Beta
0.6
52-week high
$9.99
52-week low
$2.62
Average daily volume
17K
Financial strength
Current ratio
3.037
Quick ratio
2.639
Long term debt to equity
11.271
Total debt to equity
15.567
Management effectiveness
Return on assets (TTM)
-25.68%
Return on equity (TTM)
-56.59%
Valuation
Price to revenue (TTM)
0.965
Price to book
0.1
Price to tangible book (TTM)
0.1
Price to free cash flow (TTM)
-3.606
Growth
Revenue change (TTM)
-8.54%
Earnings per share change (TTM)
-39.77%
3-year revenue growth (CAGR)
1.25%
3-year earnings per share growth (CAGR)
-14.84%
What the Analysts think about BNR
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Burning Rock Biotech stock.
BNR Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
BNR Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
BNR News
AllArticlesVideos
Burning Rock Reports Third Quarter 2024 Financial Results
GlobeNewsWire·3 weeks ago
Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024
GlobeNewsWire·3 weeks ago
NMPA Grants Marketing Approval to the First Co-Developed NGS-Based Companion Diagnostic for Lung Cancer in China
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Burning Rock Biotech stock?
Burning Rock Biotech (BNR) has a market cap of $68M as of December 22, 2024.
What is the P/E ratio for Burning Rock Biotech stock?
The price to earnings (P/E) ratio for Burning Rock Biotech (BNR) stock is 0 as of December 22, 2024.
Does Burning Rock Biotech stock pay dividends?
No, Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders as of December 22, 2024.
When is the next Burning Rock Biotech dividend payment date?
Burning Rock Biotech (BNR) stock does not pay dividends to its shareholders.
What is the beta indicator for Burning Rock Biotech?
Burning Rock Biotech (BNR) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.